Bromocriptine-induced hyperglycemia in nonobese diabetic mice: Kinetics and mechanisms of action

Review of Diabetic Studies

Volumn 4, Issue 3, 2007, Pages 185-194

  Durant, Sylvie ^a   Coulaud, Josiane ^b   Homo Delarche, Françoise ^b  

^a INSERM   (France)

^b CNRS   (France)

Author keywords

Bromocriptine; Corticosterone; Dopamine; Glucagon; Insulin; L Dopa; NOD mouse; Type 1 diabetes

Indexed keywords

BROMOCRIPTINE; CORTICOSTERONE; DOPAMINE 2 RECEPTOR; GLUCAGON; METOCLOPRAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; INSULINEMIA; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE;

EID: 37849007961     PISSN: 16136071     EISSN: 16140575     Source Type: Journal    
DOI: 10.1900/RDS.2007.4.185     Document Type: Article

References (45)

1. Berczi I. The role of prolactin in the pathogenesis of autoimmune disease. Endocr Pathol 1993. 4:178-195.
2. Hawkins TA, Gala RR, Dunbar JC. Prolactin modulates the incidence of diabetes in male and female NOD mice. Autoimmunity 1994. 18:155-162.
3. Durant S, Alves V, Coulaud J, El Hasnaoui A, Dardenne M, Homo-Delarche F. Attempts to pharmacologically modulate prolactin levels and type 1 autoimmune diabetes in the non-obese diabetic (NOD) mouse. J Autoimmun 1995. 8:875-885.
4. Ageel AM, El-Denshary ES, Abu-Jayyab AR. Effect of bromocriptine on sugar level in mice. IRCS Med Sci 1984. 12:475-476.
5. Hakanson R, Lundquist I, Rerup C. On the hyperglycaemic effect of DOPA and dopamine. Eur J Pharmacol 1967. 1(2):114-119.
6. Schmidt MJ, Root MA, Hall JL. Dopamine agonist-induced hyperglycemia in rats: structure-activity relationships and mechanisms of action. Eur J Pharmacol 1983. 90:169-177.
7. Arneric SP, Chow SA, Long JP, Fischer LJ. Dopamine ana log-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas. J Pharmacol Exp Ther 1984. 228:551-559.
8. Gerich JE. Lillie lecture 1988. Glucose couterregulation and its impact on diabetes mellitus. Diabetes 1988. 37:1608-1617.
9. Lager I. The insulin-antagonistic effect of the counter-regulatory hormones. J Intern Med 1991. 735:41-47.
10. Gerich JE. Control of glycaemia. Baillieres Clin Endocrinol Metab 1993. 7(3):551-586.
11. Sinha YN, Salocks CB, VanderLaan WP. A comparison of the effects of CB-154 and lergotrile mesylate on prolactin and growth hormone secretion in mice. Horm Metab Res 1976. 8(5):332-336.
12. Kujacic M, Hansson LO, Carlsson A. Acute dopaminergic influence on plasma adrenaline levels in the rat. Eur J Pharmacol 1995. 273:247-257.
13. Borowsky B, Kuhn CM. D1 and D2 dopamine receptors stimulate hypothalamo-pituitary-adrenal activity in rats. Neuropharmacology 1992. 31(7):671-678.
14. Foreman MM, Fuller RW, Hynes MD, Gidda JS, Nichols CL, Schaus JM, Kornfeld EC, Clemens JA. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. J Pharmacol Exp Ther 1989. 250:227-235.
15. Fuller RW, Snoddy HD. Elevation of serum corticosterone concentrations in rats by pergolide and other dopamine agonists. Endocrinology 1981. 109:1026-1032.
16. Amrani A, Jafarian-Tehrani M, Mormede P, Durant S, Pleau JM, Haour F, Dardenne M, Homo-Delarche F. Interleukin-1 effect on glycemia in the non-obese diabetic mouse at the pre-diabetic stage. J Endocrinol 1996. 148:139-148.
17. Uvnas-Moberg K, Ahlenius S, Alster P, Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 1996. 63:269-274.
18. Amrani A, Durant S, Throsby M, Coulaud J, Dardenne M, Homo-Delarche F. Glucose homeostasis in the nonobese diabetic mouse at the prediabetic stage. Endocrinology 1998. 139:1115-1124.
19. Arneric SP, Chow SA, Long JP, Fischer LJ. Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine. Diabetes 1984. 33:888-893.
20. El-Denshary EE, Ismail NA, Gagerman E, Sehlin J, Taljedal IB. Bromocriptine and insulin secretion. Biosci rep 1982. 2(2):115-116.
21. Lundquist I, Ahren B, Hansson C, Hakanson R. Monoamines in pancreatic islets of guinea pig, hamster, rat, and mouse determined by high performance liquid chromatography. Pancreas 1989. 4:662-667.
22. Ericson LE, Hakanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 1977. 13:117-124.
23. Huypens P, Ling Z, Pipeleers D, Schuit F. Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia 2000. 43:1012-1019.
24. Arneric SP, Chow SA, Bhatnagar RK, Webb RL, Fischer LJ, Long JP. Evidence that central dopamine receptors modulate sympathetic neuronal activity to the adrenal medulla to alter glucoregulatory mechanisms. Neuropharmacology 1984. 23:137-147.
25. Nagahama S, Chen YF, Oparil S. Mechanism of the depressor effect of bromocriptine in the spontaneously hypertensive rat. J Pharmacol Exp Ther 1984. 228:370-375.
26. Ahren B. Autonomic regulation of islet hormone secretion - implications for health and disease. Diabetologia 2000. 43:393-410.
27. Borelli MI, Gagliardino JJ. Possible modulatory effect of endogenous islet catecholamines on insulin secretion. BMC Endocr Disord 2001. 1:1-5.
28. Lundquist I, Ericson LE. Beta-Adrenergic insulin release and adrenergic innervation of mouse pancreatic islets. Cell Tissue Res 1978. 193:73-85.
29. Ostenson CG, Cattaneo AG, Doxey JC, Efendic S. Alpha-adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats. Am J Physiol 1989. 257:E439-E443.
30. Barseghian G, Levine R. Effect of corticosterone on insulin and glucagon secretion by the isolated perfused rat pancreas. Endocrinology 1980. 106:547-552.
31. Billaudel B, Mathias PC, Sutter BC, Malaisse WJ. Inhibition by corticosterone of calcium inflow and insulin release in rat pancreatic islets. J Endocrinol 1984. 100:227-233.
32. Delaunay F, Khan A, Cintra A, Davani B, Ling ZC, Andersson A, Ostenson CG, Gustafsson J, Efendic S, Okret S. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997. 100, 2094-2098.
33. Matthes H, Kaiser A, Stier U, Riecken EO, Rosewicz S. Glucocorticoid receptor gene expression in the exocrine and endocrine rat pancreas. Endocrinology 1994. 135:476-479.
34. George D, Bailey P. The effect of adrenergic and ganglionic blockers upon the L-dopa-stimulated release of glucagon in the rat. Proc Soc Exp Biol Med 1978. 157(1):1-4.
35. Ushiki T, Watanabe S. Distribution and ultrastructure of the autonomic nerves in the mouse pancreas. Microsc Res Tech 1997. 37:399-406.
36. Hirose H, Maruyama H, Ito K, Kido K, Koyama K, Saruta T. Effects of alpha 2- and beta-adrenergic agonism on glucagon secretion from perfused pancreata of normal and streptozocin-induced diabetic rats. Metabolism 1993. 42:1072-1076.
37. Spinedi E, Suescun MO, Hadid R, Daneva T, Gaillard RC. Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal axis: evidence for a neuroendocrine-immunological sexual dimorphism. Endocrinology 1992. 131:2430-2436.
38. El-Denshary ES, Ageel AM, el-Wakkad I, Abu-Jayyab AR. Effect of bromocriptine on lipid plasma levels in rats. Life Sci 1987. 40:1531-1535.
39. Jezova D, Jurcovicova J, Vigas M, Murgas K, Labrie F. Increase in plasma ACTH after dopaminergic stimulation in rats. Psychopharmacology (Berl) 1985. 85:201-203.
40. Shamoon H, Hendler R, Sherwin RS. Synergistic interactions among antiinsulin hormones in the pathogenesis of stress hyperglycemia in humans. J Clin Endocrinol Metab 1981. 52:1235-1241.
41. Yamada F, Inoue S, Saitoh T, Tanaka K, Satoh S, Takamura Y. Glucoregulatory hormones in the immobilization stress-induced increase of plasma glucose in fasted and fed rats. Endocrinology 1993. 132:2199-2205.
42. Porte D, Woods SC. Neural regulation of islet hormones and its role in energy balance and stress hyperglycemia. In: Ellenberg, Rifkins (eds.). Neural regulation of islet hormones and its role in energy balance and stress hyperglycemia. Series M. Medical Examination 1983. Pub.Co, New Hyde Park. pp. 175-197.
43. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000. 23:1154-1161.
44. Scislowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R, Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 1999. 23:425-431.
45. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001. 50:1008-1013.